Castle Adds to Evidence Supporting Its Skin Cancer Test Portfolio through Multiple Data Presentations at the SDPA Annual Summer Dermatology Conference 2022.
New data from pooled analysis shows DecisionDx®-Melanoma can identify patients at a high risk of melanoma recurrence within a patient population deemed low risk (T1, ≤1mm) by traditional staging systems
- Survey of 400 dermatologic clinicians demonstrates how DecisionDx®-SCC results can lead to risk-aligned treatment plan changes for patients with high-risk squamous cell carcinoma
- Castle’s laboratory workflow for MyPath® Melanoma and DecisionDx® DiffDx®-Melanoma increased the reporting of clinically actionable results to over 99% in a performance cohort of 350 archival biopsy samples